THU-219 - Efficacy and safety of paritaprevir/ritonavir, ombitasvir and dasabuvir plus/minus ribavirin for treatment of hepatitis C virus genotype 1b compensated cirrhosis in patients aged 70 years or older

Autor: Trifan, A., Prelipcean, C.C., Gheorghe, L., Curescu, M.G., Brisc, C., Bataga, S., Miftode, E., Arama, V., Chiriac, S.A., Cuciureanu, T., Sporea, I., Goldis, A., Popescu, A., Iacob, S., Cojocariu, C., Stefanescu, G., Girleanu, I., Mihai, C., Ciortescu, I., Stanciu, C.
Zdroj: In Journal of Hepatology 2017 66(1) Supplement:S284-S285
Databáze: ScienceDirect
Externí odkaz: